These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19875949)

  • 21. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
    Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
    J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
    Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
    Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
    Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
    J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
    Matsuo K; Eno ML; Im DD; Rosenshein NB; Sood AK
    Gynecol Oncol; 2010 Jan; 116(1):61-5. PubMed ID: 19840886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
    J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.